Vascular Endothelial Growth Factor and Angiogenin Levels during Fetal Development and in Maternal Diabetes

Lassus, Patrik; Teramo, Kari; Nupponen, Irmeli; Markkanen, Helene; Cederqvist, Katariina; Andersson, Sture

doi:10.1159/000073636

Cited by 22 publications

(17 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…VEGF is a key angiogenetic factor, and we observed similar cord and maternal serum VEGF concentrations in normal and GDM pregnancies. In another study, umbilical cord VEGF level was found to be lower in fetuses born to mothers with diabetes than healthy mothers [24] . As we have found no significant difference for VEGF between GDM and control groups, the possible presence of other angiogenetic factors and the probable multifactorial development of the placenta might be considered.…”

Section: Discussionmentioning

confidence: 88%

The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and Nondiabetic Controls

Madazli

Tüten

Calay³

et al. 2008

Gynecol Obstet Invest

111

View full text Add to dashboard Cite

Background/Aims: To evaluate the incidence of placental abnormalities, cord plasma erythropoietin (EPO) levels and nucleated red blood cell (NRBC) counts, maternal and cord plasma malondialdehyde (MDA) and vascular endothelial growth factor (VEGF) levels in women with gestational diabetes mellitus (GDM) and nondiabetic controls. Methods: Twenty-two women with GDM, diagnosed according to the current criteria of the American Diabetes Association, were compared with 22 controls. Maternal and cord blood and placental samples were obtained from all pregnant women. Cord plasma EPO levels and NRBC counts, maternal and cord plasma MDA and VEGF levels were determined. Placental tissues were examined histologically. Results: Maternal and cord plasma levels of MDA and cord plasma EPO levels and NRBC counts were significantly higher in GDM pregnancies (p < 0.01). The presence of villous immaturity, chorangiosis and ischemia were significantly increased in the placentas of women with GDM (p < 0.05). The maternal and cord plasma levels of MDA increased (p = 0.007 and p = 0.001, respectively), whereas VEGF decreased (p = 0.046 and p = 0.001, respectively) with the presence of villous immaturity. Conclusion: The complex process of villous development and maturity might be influenced by the maternal and fetal oxidative and angiogenetic milieu. The placenta that shows abnormalities in angiogenesis and maturation may lead to fetal hypoxia and compromise.

show abstract

Section: Discussionmentioning

confidence: 88%

The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and Nondiabetic Controls

Madazli

Tüten

Calay³

et al. 2008

Gynecol Obstet Invest

111

View full text Add to dashboard Cite

show abstract

“…A significant positive correlation exists between both angiogenic factors [18] . Moreover, a correlation has been found between VEGF and ANG levels during fetal development and in maternal diabetes [19] . Gonadotropin can not only stimulate the secretion of ANG by granulosa cells, but can also stimulate the secretion of VEGF by ovarian follicles.…”

Section: Discussionmentioning

confidence: 93%

Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation

Chen¹,

Zhang²,

Chen³

et al. 2006

WJG

View full text Add to dashboard Cite

AIM:To investigate the implication of angiogenin (ANG) in the neovascularizaton and growth of human gastric carcinoma (HGC).METHODS: ANG mRNA expression in HGC specimens obtained by surgical resection from patients with HGC were examined by RT-PCR. ANG, Ki-67, VEGF protein expression and microvessel density (MVD) in HGC specimens were detected by immunohistochemistry. RESULTS:RT-PCR showed significantly higher ANG mRNA expression (0.482 ± 0.094) in HGC tissues than in the surrounding nontumorous tissues (0.276 ± 0.019, P = 0.03). MVD within tumorous tissues increased significantly with ANG mRNA expression (r = 0.380, P = 0.001) and ANG protein expression (P < 0.01). The ANG expression levels of cancer tissues were positively correlated with VEGF (P < 0.01) and the proliferation index of cancer cells (P < 0.01). www.wjgnet.com well-moderately differentiated adenocarcinoma, and 41 patients had poorly-undifferentiated adenocarcinoma. Fourteen patients were node-negative; 46 had first station lymph node metastasis, and 8 had second or distant lymph node metastasis. Twelve tumors were TNM Ⅰ, 25 tumors were TNM Ⅱ, 20 tumors were TNM Ⅲ, and 11 tumors were TNM Ⅳ. Methods RNA extraction:Specimens were taken within 30 min after resection, and were stored at -80℃. RNA was extracted from HGC tissue and corresponding nontumorous gastric tissue using Trizol extraction reagent kit (Gibco BRL, USA), according to the instructions of the manual. Concentration and purity of RNA were determined by spectrophotometric method. Integrity of RNA was determined by electrophoresis.RT-PCR and analysis of the products: ANG primers were synthesized by the Bioasia Biotechnology Company using the method as described previously [10] . Each tube contained 5 × buffer 5 μL, 10 mmol/L dNTP 0.5 μL, DTT 1.25 μL, primers (sense, antisense) 4 μL, RNA template 1 μg, mix-enzyme 0.5 μL, DEPC solution, with a total volume of 25 μL (Titan One Tube RT-PCR system, Roche, Ger many). RT-PCR reaction condition is as follows: at 58℃ for reverse transcription for 30 min, 94℃ incubation for 2 min to terminate reverse transcription, followed by 30 cycles at 94℃ for 30 s, at 52℃ for 30 s, and at 72℃ for 60 s; With a final extension at 72℃ for 7 min. RT-PCRs were run in a Bio-rad thermocycler. The results were analysed in a Bio-rad GelDoc-1000 system, relative to the levels of β actin as the control. Immunohistochemistry: ANG multiclonal antibody 1:25 was purchased from American Santa Cruz Co. VEGF-C multiclonal antibody (ready to use) was provided by American Zymed Co. Monoclonal antibody of CD34 (QBEnd/10, ready to use) and monoclonal antibody of Ki-67 (MIB-1, 1:50) were supplied by American NeoMarkers Co. All operations were done according to the instructions of the manufacturers. Positive specimens were used as positive controls and PBS in substitution of the first antibody was used as a negative control at the same time. ANG protein expression [8] : Cytoplasm of gastric carcinoma cells was stained brown. According to the staining intensity of the tum...

show abstract

“…Among the angiogenic factors vascular endothelial growth factor (VEGF), fibroblast growth factor (FGF-2), angiopoietins, placental growth factor (PlGF), tumor necrosis factor (TNFA), interleukin 8 (IL-8) and insulin-like growth factors 1 and 2 (IGF1, IGF2) have been identified, of which TNFA can as well act in an angiostatic manner [24]. Most of them are altered in maternal diabetes mellitus [25][26][27][28][29][30][31]. The effect of these factors on the early processes in angiogenesis is unclear and awaits investigation.…”

Section: The Placenta In Early Diabetic Pregnancymentioning

confidence: 99%

The Placenta in a Diabetic Pregnancy

Hiden

Desoyé

2017

A Practical Manual of Diabetes in Pregnancy

View full text Add to dashboard Cite

Vascular Endothelial Growth Factor and Angiogenin Levels during Fetal Development and in Maternal Diabetes

Cited by 22 publications

References 33 publications

The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and Nondiabetic Controls

The Incidence of Placental Abnormalities, Maternal and Cord Plasma Malondialdehyde and Vascular Endothelial Growth Factor Levels in Women with Gestational Diabetes Mellitus and Nondiabetic Controls

Increased expression of angiogenin in gastric carcinoma in correlation with tumor angiogenesis and proliferation

The Placenta in a Diabetic Pregnancy

Contact Info

Product

Resources

About